Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa

被引:19
作者
Jassat, Waasila [1 ,2 ]
Karim, Salim S. Abdool [3 ,4 ]
Ozougwu, Lovelyn [1 ,2 ]
Welch, Richard [1 ,2 ]
Mudara, Caroline [1 ]
Masha, Maureen [1 ,2 ]
Rousseau, Petro [5 ]
Wolmarans, Milani [5 ]
Selikow, Anthony [6 ]
Govender, Nevashan [1 ]
Walaza, Sibongile [1 ,7 ]
von Gottberg, Anne [1 ,8 ]
Wolter, Nicole [1 ,8 ]
Pisa, Pedro Terrence [2 ,9 ]
Sanne, Ian [2 ,10 ]
Govender, Sharlene [2 ]
Blumberg, Lucille [1 ,2 ]
Cohen, Cheryl [1 ]
Groome, Michelle J. [1 ,8 ]
机构
[1] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, 1 Modderfontein Rd, ZA-2192 Johannesburg, South Africa
[2] Right Care, Pretoria, South Africa
[3] Ctr AIDS Programme Res South Afr, Durban, South Africa
[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[5] Natl Dept Hlth, Pretoria, South Africa
[6] CSIR, Pretoria, South Africa
[7] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa
[8] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa
[9] Univ Pretoria, Fac Hlth Sci, Dept Human Nutr & Dietet, Pretoria, South Africa
[10] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
关键词
COVID-19; hospital admissions; mortality; Omicron BA; 4; 5;
D O I
10.1093/cid/ciac921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Admission incidence risk and in-hospital mortality decreased in the Omicron BA.1/BA.2 wave, reducing even further in the Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased. Background In this study, we compared admission incidence risk and the risk of mortality in the Omicron BA.4/BA.5 wave to previous waves. Methods Data from South Africa's SARS-CoV-2 case linelist, national COVID-19 hospital surveillance system, and Electronic Vaccine Data System were linked and analyzed. Wave periods were defined when the country passed a weekly incidence of 30 cases/100 000 population. In-hospital case fatality ratios (CFRs) during the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves were compared using post-imputation random effect multivariable logistic regression models. Results The CFR was 25.9% (N = 37 538 of 144 778), 10.9% (N = 6123 of 56 384), and 8.2% (N = 1212 of 14 879) in the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves, respectively. After adjusting for age, sex, race, comorbidities, health sector, and province, compared with the Omicron BA.4/BA.5 wave, patients had higher risk of mortality in the Omicron BA.1/BA.2 wave (adjusted odds ratio [aOR], 1.3; 95% confidence interval [CI]: 1.2-1.4) and Delta wave (aOR, 3.0; 95% CI: 2.8-3.2). Being partially vaccinated (aOR, 0.9; 95% CI: .9-.9), fully vaccinated (aOR, 0.6; 95% CI: .6-.7), and boosted (aOR, 0.4; 95% CI: .4-.5) and having prior laboratory-confirmed infection (aOR, 0.4; 95% CI: .3-.4) were associated with reduced risks of mortality. Conclusions Overall, admission incidence risk and in-hospital mortality, which had increased progressively in South Africa's first 3 waves, decreased in the fourth Omicron BA.1/BA.2 wave and declined even further in the fifth Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.
引用
收藏
页码:1468 / 1475
页数:8
相关论文
共 50 条
  • [41] Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine
    Nham, Eliel
    Kim, Jineui
    Lee, Jungmin
    Park, Heedo
    Kim, Jeonghun
    Lee, Sohyun
    Choi, Jaeuk
    Kim, Kyung Taek
    Yoon, Jin Gu
    Hwang, Soon Young
    Song, Joon Young
    Cheong, Hee Jin
    Kim, Woo Joo
    Park, Man-Seong
    Noh, Ji Yun
    IMMUNE NETWORK, 2023, 23 (06)
  • [42] Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
    Carlin, Aaron F.
    Clark, Alex E.
    Garretson, Aaron F.
    Bray, William
    Porrachia, Magali
    Santos, AsherLev T.
    Rana, Tariq M.
    Chaillon, Antoine
    Smith, Davey M.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [43] Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
    Ciesla, Allison Avrich
    Wiegand, Ryan E.
    Smith, Zachary R.
    Britton, Amadea
    Fleming-Dutra, Katherine E.
    Miller, Joseph
    Accorsi, Emma K.
    Verani, Jennifer R.
    Shang, Nong
    Derado, Gordana
    Pilishvili, Tamara
    Link-Gelles, Ruth
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
  • [44] Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5-specific response
    Baker Jr, Ryan
    Lawlor, Rebecca
    Smith, Maeve
    Price, Jessica
    Eaton, Ashley
    Lover, Andrew
    Alfandari, Dominique
    Reinhart, Peter
    Arcaro, Kathleen F.
    Osborne, Barbara A.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [45] Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
    Kopel, Hagit
    Nguyen, Van Hung
    Bogdanov, Alina
    Winer, Isabelle
    Boileau, Catherine
    Ducruet, Thierry
    Zeng, Ni
    Winer-Jones, Jessamine P.
    Esposito, Daina B.
    Bausch-Jurken, Mary
    Beck, Ekkehard
    Bonafede, Machaon
    Mansi, James A.
    VACCINES, 2024, 12 (10)
  • [46] Differences in Clinical Presentation of COVID-19 in Children Hospitalized During Domination of Early (BA.1, BA.2) and Late (BA.5, BA.2.75, BQ.1 and XBB.1.5) SARS-CoV-2 Omicron Subvariants
    Pokorska-Spiewak, Maria
    Pawlowska, Malgorzata
    Ciechanowski, Przemyslaw
    Peregrym, Michal
    Dobrzeniecka, Anna
    Sobolewska-Pilarczyk, Malgorzata
    Franczak, Justyna
    Majda-Stanislawska, Ewa
    Szczepanska, Barbara
    Zaleska, Izabela
    Flisiak, Robert
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2024, 43 (02) : 149 - 154
  • [47] SARS-CoV2 Nonstructural Protein, But Not The Omicron Ba.4/5 Mutant, Suppresses YAP Transcriptional Activity In The Heart
    Meng, Fansen
    Tsai, Chang-Ru
    Kim, Jong H.
    Li, Xiao
    Steimle, Jeff
    Liu, Shijie
    Xie, Bing
    Li, Rich Gang
    Martin, James F.
    CIRCULATION RESEARCH, 2023, 133
  • [48] A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population
    Camacho, Jorge
    Albert, Eliseo
    Alvarez-Rodriguez, Beatriz
    Rusu, Luciana
    Zulaica, Joao
    Moreno, Alicia Rodriguez
    Peiro, Salvador
    Geller, Ron
    Navarro, David
    Gimenez, Estela
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (04)
  • [49] Updated estimates of excess total mortality in Italy during the circulation of the BA.2 and BA.4-5 Omicron variants: April-July 2022
    Alicandro, Gianfranco
    Gerli, Alberto Giovanni
    Remuzzi, Giuseppe
    Centanni, Stefano
    La Vecchia, Carlo
    MEDICINA DEL LAVORO, 2022, 113 (05):
  • [50] Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
    Wee, Liang En
    Tay, An Ting
    Chiew, Calvin
    Young, Barnaby Edward
    Wong, Betty
    Lim, Ruth
    Li Lee, Ching
    Tan, Joyce
    Vasoo, Shawn
    Lye, David Chien
    Tan, Kelvin Bryan
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (10) : 1328 - 1333